These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 20662003)

  • 1. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth.
    Peiris-Pagès M; Harper SJ; Bates DO; Ramani P
    J Pathol; 2010 Oct; 222(2):138-47. PubMed ID: 20662003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
    Zins K; Kovatchki D; Lucas T; Abraham D
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
    Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
    Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.
    Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO
    J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts.
    Segerström L; Fuchs D; Bäckman U; Holmquist K; Christofferson R; Azarbayjani F
    Pediatr Res; 2006 Nov; 60(5):576-81. PubMed ID: 16988184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
    Kaneko S; Ishibashi M; Kaneko M
    Cancer Sci; 2008 Jun; 99(6):1209-17. PubMed ID: 18384433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo.
    Rennel ES; Varey AH; Churchill AJ; Wheatley ER; Stewart L; Mather S; Bates DO; Harper SJ
    Br J Cancer; 2009 Oct; 101(7):1183-93. PubMed ID: 19707198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.
    Catena R; Larzabal L; Larrayoz M; Molina E; Hermida J; Agorreta J; Montes R; Pio R; Montuenga LM; Calvo A
    Mol Cancer; 2010 Dec; 9():320. PubMed ID: 21194429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney development.
    Bevan HS; van den Akker NM; Qiu Y; Polman JA; Foster RR; Yem J; Nishikawa A; Satchell SC; Harper SJ; Gittenberger-de Groot AC; Bates DO
    Nephron Physiol; 2008; 110(4):p57-67. PubMed ID: 19039247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.
    Varey AH; Rennel ES; Qiu Y; Bevan HS; Perrin RM; Raffy S; Dixon AR; Paraskeva C; Zaccheo O; Hassan AB; Harper SJ; Bates DO
    Br J Cancer; 2008 Apr; 98(8):1366-79. PubMed ID: 18349829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
    Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
    J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.
    Perrin RM; Konopatskaya O; Qiu Y; Harper S; Bates DO; Churchill AJ
    Diabetologia; 2005 Nov; 48(11):2422-7. PubMed ID: 16193288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.
    Rennel ES; Hamdollah-Zadeh MA; Wheatley ER; Magnussen A; Schüler Y; Kelly SP; Finucane C; Ellison D; Cebe-Suarez S; Ballmer-Hofer K; Mather S; Stewart L; Bates DO; Harper SJ
    Eur J Cancer; 2008 Sep; 44(13):1883-94. PubMed ID: 18657413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.
    Eggert A; Ikegaki N; Kwiatkowski J; Zhao H; Brodeur GM; Himelstein BP
    Clin Cancer Res; 2000 May; 6(5):1900-8. PubMed ID: 10815914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.
    Rennel E; Waine E; Guan H; Schüler Y; Leenders W; Woolard J; Sugiono M; Gillatt D; Kleinerman E; Bates D; Harper S
    Br J Cancer; 2008 Apr; 98(7):1250-7. PubMed ID: 18349828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-angiogenic isoforms of VEGF in health and disease.
    Qiu Y; Hoareau-Aveilla C; Oltean S; Harper SJ; Bates DO
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1207-13. PubMed ID: 19909248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.
    Hamdollah Zadeh MA; Amin EM; Hoareau-Aveilla C; Domingo E; Symonds KE; Ye X; Heesom KJ; Salmon A; D'Silva O; Betteridge KB; Williams AC; Kerr DJ; Salmon AH; Oltean S; Midgley RS; Ladomery MR; Harper SJ; Varey AH; Bates DO
    Mol Oncol; 2015 Jan; 9(1):167-78. PubMed ID: 25224594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.
    Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO
    J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingolipid modulation of angiogenic factor expression in neuroblastoma.
    Li MH; Hla T; Ferrer F
    Cancer Prev Res (Phila); 2011 Aug; 4(8):1325-32. PubMed ID: 21576349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.